Introduction
How a peptide is administered is as important as which peptide is chosen. Route of administration determines bioavailability, onset of action, half-life in circulation, and ultimately clinical outcome. This article covers every major delivery method used in therapeutic peptide protocols, with practical guidance on reconstitution, storage, and dosing.
Why Route of Administration Matters
Peptides are chains of amino acids — and like all proteins, they are vulnerable to enzymatic degradation. The digestive system is particularly hostile: proteases in the stomach and small intestine cleave peptide bonds rapidly, destroying most peptides before they reach systemic circulation. This is why the majority of therapeutic peptides cannot be taken orally in standard form.
The choice of delivery route must account for:
- Peptide stability in the chosen medium
- Desired speed of onset
- Target tissue (local vs. systemic)
- Patient compliance and practical feasibility
- Half-life and dosing frequency requirements
Subcutaneous Injection (SubQ)
Subcutaneous injection — into the fatty tissue just beneath the skin — is the gold standard for most therapeutic peptides. It provides:
- Consistent bioavailability — typically 80–100% for most peptides
- Slow, sustained absorption — from the subcutaneous depot into systemic circulation
- Ease of self-administration — using insulin syringes (typically 29–31 gauge, 0.5–1 mL)
- Minimal discomfort — when injected into the abdomen, thigh, or upper arm
Common injection sites: lower abdomen (2 inches from navel), outer thigh, upper arm. Rotate sites to prevent lipodystrophy.
Peptides commonly delivered SubQ: BPC-157, TB-500, Ipamorelin, CJC-1295, Thymosin Alpha-1, PT-141, Epithalon, Sermorelin.
Intramuscular Injection (IM)
Intramuscular injection delivers peptide directly into muscle tissue, providing faster absorption than SubQ due to higher vascularity. IM is less commonly used for peptides than SubQ but may be preferred for:
- Peptides requiring rapid onset
- Larger injection volumes
- Specific tissue-targeting (e.g., local BPC-157 injection near an injury site)
Common IM sites: deltoid, vastus lateralis (outer thigh), gluteus medius.
Intranasal Administration
Several peptides are available in intranasal formulations, offering a non-injectable route with reasonable CNS bioavailability due to the olfactory pathway bypassing the blood-brain barrier.
Peptides with intranasal protocols:
- Semax — cognitive enhancement; intranasal is the primary route
- Selank — anxiolytic and nootropic; intranasal standard
- PT-141 — available as a nasal spray (Vyleesi, FDA-approved)
- Oxytocin — intranasal for social bonding and anxiety protocols
Bioavailability via intranasal route is lower than injection (typically 10–40%) but sufficient for CNS-targeted peptides where direct olfactory transport compensates.
Oral Peptides
Most peptides are destroyed by gastric acid and proteases before absorption. However, a small number are orally active due to:
- Resistance to proteolytic degradation (cyclic peptides, D-amino acid substitutions)
- Enteric coating protecting the peptide through the stomach
- Absorption via specific intestinal transporters
Orally active peptides:
- BPC-157 — the arginate salt form (BPC-157 Arginate) has demonstrated oral activity, particularly for GI conditions
- Berberine-conjugated peptides — research-stage
- Cyclic peptides — engineered for oral bioavailability (emerging class)
Topical and Transdermal
Topical peptides are used primarily for local skin effects — collagen stimulation, wound healing, and anti-aging. Systemic bioavailability via transdermal routes is generally low for larger peptides due to molecular size limitations.
Common topical peptides:
- GHK-Cu (Copper Peptide) — widely used in skincare for collagen synthesis and wound repair
- Matrixyl (Palmitoyl Pentapeptide-4) — anti-aging cosmetic peptide
- Argireline (Acetyl Hexapeptide-3) — topical muscle-relaxing peptide
Transdermal patches and penetration enhancers (DMSO, liposomal carriers) can improve systemic delivery for smaller peptides.
Reconstitution Protocol
Most injectable peptides are supplied as lyophilized (freeze-dried) powder and must be reconstituted before use. Standard protocol:
- Gather supplies: peptide vial, bacteriostatic water (BW), insulin syringe, alcohol swabs
- Clean the vial tops with alcohol swabs and allow to dry
- Draw bacteriostatic water — typically 1–2 mL per vial (adjust based on desired concentration)
- Inject BW slowly into the peptide vial, directing the stream down the side of the vial — never directly onto the powder
- Gently swirl — do not shake; shaking can denature the peptide
- Allow to dissolve fully — the solution should be clear; discard if cloudy or particulate
- Label the vial with peptide name, concentration, and reconstitution date
Example concentration calculation: 5 mg peptide + 2 mL BW = 2,500 mcg/mL. A 100 mcg dose = 0.04 mL (4 units on an insulin syringe).
Storage Guidelines
| State | Storage | Stability |
|---|---|---|
| Lyophilized (unreconstituted) | Refrigerator (2–8°C) or freezer | 1–2 years (varies by peptide) |
| Reconstituted in BW | Refrigerator (2–8°C) | 4–6 weeks typically |
| Reconstituted in sterile water | Refrigerator; use within 24–48 hours | Very short — BW preferred |
Avoid repeated freeze-thaw cycles. Keep away from light. Never use a peptide solution that has changed color or become cloudy.
Dosing Principles
Peptide dosing is highly peptide-specific, but general principles apply:
- Start low, titrate up — begin at the lower end of the therapeutic range and adjust based on response and tolerance
- Timing matters — GH secretagogues are most effective when dosed before sleep or fasted, to align with natural GH pulsatility
- Cycling — many peptides are cycled (e.g., 5 days on / 2 days off, or 3 months on / 1 month off) to prevent receptor desensitization
- Synergistic stacking — combining complementary peptides can allow lower individual doses while achieving greater effect
Specific dosing protocols are provided in each peptide's dedicated article throughout this hub.
Conclusion
Delivery method is a critical determinant of peptide efficacy. Subcutaneous injection remains the most reliable route for systemic peptides, while intranasal, oral, and topical routes offer targeted alternatives for specific applications. Proper reconstitution, storage, and dosing discipline are non-negotiable for safe and effective peptide therapy.